The Market for Pharmaceuticals in Brazil, Russia, India & China

A new report that evaluates the real status, opportunities and threats for pharmaceutical companies now and in the future.

For years the huge markets of Brazil, Russia, India and China (the BRIC economies) have promised much and delivered little. Ongoing political and economic issues have held them back from realising their true potential in the global market. But is all that set to change?

Consider the long term?
In less than 40 years time, the BRIC economies together could be larger than the G6 in US dollar terms;
In US dollar terms, China could overtake Germany in the next four years, Japan by 2015 and the US by 2039;
Source: Goldman Sachs Global Economics Paper No:99. Reproduced with permission.

This is evolution not revolution, and change will be progressive. Common characteristics to be found among the four markets include low levels of health expenditure, wide unmet clinical and social need and variable health provision. The real opportunities lay in the future, where steady growth in BRIC markets will erode the commercial differences with the established markets of North America, Japan and Europe.

Effective planning is vital, and impartial, thoroughly researched information is essential to fully appreciate the current status as a basis for future development. That is why Espicom Business Intelligence, the leading provider of market intelligence, has published the 308-page management report The Market for Pharmaceuticals in Brazil, Russia, India & China. In addition to highly detailed chapters on each market, the report provides a thought-provoking and comparative examination of the BRIC economies, putting opportunities into their current and future context.